Clinical Trial Update: Immunogenicity and Safety Study of Serum-Free Avonex [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the immunogenicity and safety of Serum-Free Avonex in multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Avonex (Interferon beta-1a)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED